Lymphoma, T-Cell

Oncology
2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
1
CopanlisibPhase 1Small Molecule1 trial
Active Trials
NCT04233697Withdrawn0Est. Jul 2023
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
1
GCC2005Phase 11 trial
Active Trials
NCT06699771RecruitingEst. Aug 2027
Takeda
TakedaTOKYO, Japan
1 program
MOOVCAREN/A1 trial
Active Trials
NCT03154710Terminated52Est. Mar 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
GC BiopharmaGCC2005
BayerCopanlisib
TakedaMOOVCARE

Clinical Trials (3)

Total enrollment: 52 patients across 3 trials

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Start: Mar 2025Est. completion: Aug 2027
Phase 1Recruiting

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Start: Feb 2020Est. completion: Jul 20230
Phase 1Withdrawn

Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response

Start: Jul 2017Est. completion: Mar 202152 patients
N/ATerminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 52 patients
3 companies competing in this space